Who said anything about it being contingent for approval? I am very hopeful on AVXL gaining a positiove opinion. I was commenting on a previous post:
Landmark Case
Blarcamesine isn’t a follow-on product. It’s the first major Sigma-1 receptor agonist ever to reach a full regulatory hearing for Alzheimer’s disease. That fact alone transforms its review into a precedent-setting exercise.
Taking this into consideration and realizing that the entire Anavex platform is on pause, everything riding on this tiny bio company that has not marketed any drug in their history to successfully and reliably launch, well, the CHMP might want to dot some i's and cross some t's...
I would imagine that if we get the news we want by Friday, we may finally see that short squeeze. Then this 42 person company may have the time to initiate new trials for Parkinsons, Fragile X, file for regulatory approvals worldwide, plus launch and market a new drug for a major unmet need throughout Europe. I'm just looking at this with my eyes wide open.
You ask: "Is this just to push small companies into the arms of a BP?" I say, yeah sure... (lol, Godfather reference)
Market Data 
Markets 
AI
